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Background: The purpose of the present work is to mask the intensely bitter taste of Itopride HCl and to formulate
an Oro dispersible tablet (ODT) of the taste-masked drug by incorporation of microspheres in the tablets for use in
specific populations viz. pediatrics, geriatrics and patients experiencing difficulty in swallowing.
Methods: With this objective in mind, microspheres loaded with Itopride HCl were prepared by solvent
evaporation method using acetone as solvent for pH-sensitive polymer, Eudragit EPO and light liquid paraffin as the
encapsulating medium. The prepared microspheres were characterized with regard to yield, drug content, flow
properties, particle size and size distribution, surface features, in vitro drug release and taste. The ODTs so prepared
from these microspheres were evaluated for hardness, thickness, weight variation, friability, disintegration time, drug
content, wetting time, water absorption ratio, moisture uptake, in vitro dispersion, in vitro disintegration, in vitro
drug release and stability.
Results: The average size of microspheres was found to be satisfactory in terms of the size and size distribution.
Microspheres prepared were of a regular spherical shape. Comparison of the dissolution profiles of microspheres in
different pH media showed that microspheres having drug: polymer ratio of 1:2 produced a retarding effect in
simulated salivary fluid (pH 6.8) and were further used for formulation into ODTs after addition of suitable amounts
of excipients such as superdisintegrant, diluent, sweetener and flavor of directly compressible grade.
Conclusions: Effective taste-masking was achieved for Itopride HCl by way of preparation of microspheres and
ODTs of acceptable characteristics.
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Among the different routes of administration, oral route
of administration continues to be the most preferred
route due to various advantages including ease of inges-
tion, avoidance of pain, versatility and most importantly
patient compliance. The different dosage forms include
tablets, capsules and oral liquid preparations. The im-
portant drawback of tablet and capsule dosage forms for
pediatric and geriatric patients has been difficulty in swal-
lowing [1]. To overcome this problem, formulators have* Correspondence: agrawal.shyam01@gmail.com
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reproduction in any medium, provided the orconsiderably dedicated their effort to develop a novel type
of tablet dosage form for oral administration called “Oro
Dispersible Tablet”, (ODT) i.e., one, which disintegrates and
dissolves rapidly in saliva without the need of water [2].
United States Food and Drug Administration (FDA)
defined ODT as “A solid dosage form containing medicinal
substance or active ingredient which disintegrates rapidly
usually within a matter of seconds when placed upon the
tongue [3].” The disintegration time for ODTs generally
ranges from several seconds to about a min.
The two key parameters that need to be considered in the
development of ODTs are taste masking of bitter drug and
the disintegration time. Various taste-masking technologies
have been extensively reviewed [4-6]. Solvent evaporation is
a relatively simple and convenient method for the prepar-
ation of taste-masked microspheres. The drug particles ared. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Different ratios of Drug: polymer for preparation of microspheres (mean±SD, n =3)


























% release of drug
in simulated
saliva in 60 sec
A1 200 200 200 40 2.0 600 69.3 ± 1.2 186.3 ± 2.5 37.86 ± 0.5 94.65 ± 1.2 6.31 ± 0.09
A2 200 400 200 40 2.0 600 72.3 ± 1.5 197.2 ± 2.8 32.02 ± 0.2 96.09 ± 1.3 1.61 ± 0.06
A3 200 600 200 40 2.0 600 77.6 ± 2.1 202.2 ± 3.7 24.32 ± 0.3 97.28 ± 1.6 1.57 ± 0.04
A4 200 800 200 40 2.0 600 75.9 ± 1.7 278.6 ± 4.2 19.23 ± 0.1 96.15 ± 1.4 1.51 ± 0.05
A5 200 1000 200 40 2.0 600 68.3 ± 2.4 327.9 ± 3.6 16.17 ± 0.2 97.05 ± 1.3 1.43 ± 0.07
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into the saliva but allow the release of the drug in the
stomach. The most widely used solvent systems in solvent
evaporation process are methylene chloride/water [7] and
acetone/light liquid paraffin [8-11]. This technology has been
applied to mask the bitter taste of therapeutic agents such as
bacampicilin [8,12] pseudoephedrine [7] and cefuroxime
axetil [10].
Itopride Hydrochloride is used for the management
of Nonulcer dyspepsia (NUD), gastro-esophageal reflux
disease (GERD), gastritis, diabetes gastro paresis and
functional dyspepsia. It is a newer gastroprokinetic agent
with anti cholinesterase activity as well as D2 receptor
antagonistic activity and is being used for the symp-
tomatic treatment of various gastrointestinal motility
disorders [13]. Itopride HCl is available in market inTable 2 Taste-masked Itopride HCl microsphere ingredients, p











B1 200 400 1.6 200 40
B2 200 400 1.8 200 40
B3 200 400 2.0 200 40
B4 200 400 2.2 200 40
C1 200 400 1.8 80 40
C2 200 400 1.8 120 40
C3 200 400 1.8 160 40
C4 200 400 1.8 180 40
D1 200 400 1.8 160 20
D2 200 400 1.8 160 30
D3 200 400 1.8 160 40
D4 200 400 1.8 160 50
E1 200 400 1.8 160 40
E2 200 400 1.8 160 40
E3 200 400 1.8 160 40
E4 200 400 1.8 160 40
E5 200 400 1.8 160 40the form of immediate release tablets/capsules, for e.g.
“GANATONW” sold by Abbott Laboratories (Abbott
Park, Illinois). Itopride HCl is a highly water soluble and
intensely bitter drug. Thus, it was envisaged to mask the
taste of Itopride HCl by way of making microspheres
prior to formulating ODTs with good mouth feel. To the
best of our knowledge, it is the first time such an attempt
has been made that would explore the rational approach
of incorporating taste-masked microspheres of Itopride
HCl in an orally disintegrating tablet.
Materials and methods
Materials
Itopride HCl was obtained as a gift from Ranbaxy Labora-
tories Ltd (Gurgaon, India). Aminoalkyl methacrylate












600 70.8 ± 1.3 285.5 ± 1.2 24.76 ± 0.4 99.04 ± 0.5
600 81.89 ± 1.4 216.9 ± 1.7 24.05 ± 0.7 96.20 ± 0.07
600 78.19 ± 1.5 197.8 ± 2.4 23.84 ± 0.3 95.36 ± 0.4
600 72.6 ± 1.6 121.1 ± 1.9 23.96 ± 0.5 95.84 ± 0.2
600 Batch Failed
600 61.59 ± 2.3 283.0 ± 2.6 27.56 ± 0.1 99.21 ± 0.1
600 82.32 ± 2.5 238.5 ± 1.5 25.94 ± 0.2 98.58 ± 0.2
600 80.18 ± 2.1 201.1 ± 3.5 24.83 ± 0.4 96.84 ± 0.4
600 Batch Failed
600 73.84 ± 1.6 302.5 ± 2.4 26.17 ± 0.6 99.46 ± 0.5
600 82.13 ± 1.7 264.7 ± 1.0 25.96 ± 0.7 98.66 ± 0.7
600 75.58 ± 2.5 182.4 ± 3.1 25.47 ± 0.8 96.80 ± 0.3
200 Batch Failed
400 84.31 ± 3.0 296.58± 2.2 25.36 ± 0 .7 96.35 ± 0.5
600 82.11 ± 2.8 214.60± 3.2 25.43 ± 0.09 96.66 ± 0.3
800 77.74 ± 3.2 174.64± 2.0 25.44 ± 0.7 96.66 ± 0.2
1000 62.76 ± 2.8 128.5 ± 1.8 24.96 ± 0.4 94.48 ± 0.1
Shah et al. DARU Journal of Pharmaceutical Sciences 2012, 20:24 Page 3 of 12
http://www.darujps.com/content/20/1/24Degussa India Private Ltd (Mumbai, India). Magnesium
stearate was kindly supplied by Unichem (New Delhi,
India). Other excipients that were purchased included
mannitol (Pearlitol, CDH (P) Ltd., New Delhi, India),
sodium stearyl fumarate (ITM Chem. Pvt. Ltd. Mumbai),
Nutra Sweet (Aspartame, Kawarlal and sons, Chennai,
India) and crospovidone (Polyplasdone XL-10, Nanz Med
Sciences Pharma Pvt. Ltd., Delhi, India). All other chemicals




Microspheres were prepared by the solvent evapor-
ation method previously reported and modified for
our purpose [10,12]. Firstly, Eudragit EPO was dis-
solved in acetone on a magnetic stirrer to obtain uni-
form mixing. Itopride HCl was then added to the
above solution. To this mixture, magnesium stearate
was added. The polymer drug solution so obtained
was injected into light liquid paraffin at a low stirring
speed (200–600 rpm) of mechanical stirrer for about
3 h until all the acetone evaporated. n-Hexane/petroleum
ether was added to the system for hardening of the
microspheres and to accelerate settling. Microspheres
were separated by decantation following filtration through
a Whatman filter paper (No. 41). Microspheres were then
washed with n-hexane and the washed microspheres were
dried in an oven maintained at 37°C for 24 h. Dried
microspheres were stored at room temperature. Various
drug: polymer ratios were selected for the formulation of
microspheres (Table 1). The formulation parameters and
process parameters for different batches of microspheres
were evaluated (Table 2).
Characterization of Microspheres
Percentage Yield
The prepared microspheres were completely dried in an
oven maintained at 37°C for 24 h and then weighed. The
percentage yield of microspheres was calculated accord-
ing to the following equation:
% yield ¼ Practicalyield
Theoreticalyield
 100 ð1Þ
Drug Loading and Drug content [14]
The microspheres (100 mg) were crushed in pestle-
mortar and then stirred with 100 ml 0.1 N HCl (pH 1.2)
for 2 hr to ensure complete elution of drug. The read-
ings were taken in triplicate. The Itopride HCl content
of the microspheres was calculated using a standardcalibration curve prepared with UV-Visible spectropho-
tometer at 258 nm after suitable dilution.




Drug loading %ð Þ ¼ Weight of drug inmicrospheres
Weight of drug initiallyadded
 100
ð3Þ
Evaluation of flow properties of microspheres
The prepared microspheres were evaluated for flow
properties [15] including bulk density (Db), tapped density
(ρt), Carr’s compressibility index (I) [16], Hausner ratio (H)
[17] and Angle of Repose (θ).
Micromeritics of microspheres
The size distribution and average size of the mic-
rospheres were determined by sieve analysis using
American society for testing of materials (ASTM) sieves.
A set of 12 sieves ranging in size from 1.18 mm (# 16) to
75 microns (# 200) mounted on a sieve shaker unit was
used. Amount of microspheres remaining on each sieve
was then weighed and calculated [18].
Scanning Electron Microscopy Analysis of the Microspheres
The drug and microspheres were characterized further
using a scanning electron microscope (JEOL JSM5200,
Japan Electron Optics Ltd., Japan) after gold sputtering.
Shapes and surface characteristics of the microspheres
were investigated and photographed.
Thermal analysis of the microspheres
Differential scanning calorimetric (DSC) experiments
were performed on Itopride Hydrochloride, Eudragit
EPO and drug-loaded microspheres (Shimadzu TA
60WS, Japan). Accurately weighted samples (2–5 mg)
were sealed in flat bottom aluminum pans and heated
from ambient to 200°C at a rate of 10°C/min in a nitro-
gen atmosphere (flow rate, 10 ml/min).
Fourier-Transform IR (FTIR) studies
Fourier Transform Infrared (FTIR) scans of Itopride
HCl, Eudragit EPO, Physical ad-mixture of drug plus
Eudragit EPO and drug-loaded microspheres were
recorded (Jasco FTIR-410, Japan). All the discs were pre-
pared in KBr press.
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In vitro drug release studies were carried out using USP
XXIV dissolution apparatus II. [19]Accurately weighed
Itopride HCl microspheres (equivalent to 10 mg of Ito-
pride HCl) were added to the medium under test. The
test was carried out in pH 1.2 (900 ml) and pH 6.8 phos-
phate buffer (900 ml) equilibrated at 37 ± 0.5°C. The
paddle was rotated at 50 rpm. At specific times of 5, 10,
15 and 30 min, aliquots of the dissolution medium were
withdrawn and which replaced with 10 ml of fresh dis-
solution medium. The collected samples were analyzed
using UV spectrophotometer at 258 nm.
Preparation of the ODTs
Orodispersible tablets of Itopride HCl microspheres
were prepared by direct compression technique using
crospovidone as a superdisintegrant. The optimization
of tablet disintegration is commonly done by means of
the disintegration critical concentration. Below this con-
centration the tablet disintegration time is inversely pro-
portional to the disintegrant concentration. Above the
critical concentration, the disintegration time remains
approximately constant or even increased [20]. The
selected batch of microspheres were incorporated into
tablets on the basis of drug loading so as to give the
required dose of 50 mg/tablet. The microspheres were
blended along with the other excipients (super-disinte-
grant, sweetener, flavor and lubricant) and processed to
allow direct compression tabletting in a single punch
tablet machine (Cadmach, India) using 11-mm round,
convex-faced, beveled edge tooling (Panacea tools Ltd.,
New Delhi).
Evaluation and characterization of Tablets
Thickness of tablets was assessed using a Vernier caliper.
The hardness of the tablets was determined by using
Monsanto hardness tester (Pharma Chem. Machineries,
India) and about 4–6 kg/cm2 was considered adequate
for mechanical stability of ODT [21]. Uniformity of weight
was also determined as per Indian Pharmacopoeia (IP) [22].
As per USP 30-NF 25, friability of twenty six tablets was
determined using Roche Friabilator (EI Products, India)
[21]. The India Pharmacopoeia prescribes a friability <1%
for good mechanical resistance.
Determination of drug content
Six tablets were crushed to a powder and powder
equivalent to 10 mg Itopride HCl was taken and dis-
solved in 0.1 N HCl to extract the active ingredient.
The solution was filtered through Whatmann filter
paper (no. 41). After suitable dilution with 0.1 N HCl,
the drug content was analyzed by UV spectrophotom-
eter at 258 nm [23].In vitro evaluation of tablets
Wetting time and water absorption ratio of tablets were
determined as per method prescribed in the literature
earlier [24]. Moisture uptake test was performed in con-
ditions prescribed in literature [25]. In vitro dispersion
time was measured by dropping a tablet without disc in
a measuring cylinder containing 10 ml of phosphate buf-
fer pH 6.8 (simulated saliva fluid and time required for
complete dispersion of a tablet was measured. In vitro
disintegration test was carried out using USP XXIV tab-
let disintegration test apparatus (Pharma Test, Germany)
[26]. The time for disintegration of ODTs is generally
less than one min and actual disintegration time that pa-
tient can experience ranges from 5–30 seconds. In-vitro
Dissolution studies [27] were performed using USP XXIV
Type II dissolution paddle apparatus (Lab India, DS
8000, India). The dissolution test was performed using
900 ml of 0.1 N HCl buffer at 37 ± 0.5°C. The speed of
rotation of paddle was set at 50 rpm. Samples of com-
mercial product GANATON and oral disintegrating tab-
let (F2) of Itopride HCL (equivalent to 50 mg of Itopride
HCL) were introduced in the dissolution medium. The
dissolution tests were carried out for 2 h with sampling
time intervals of 2, 5, 10, 15, 30, 45, 60, 90 and 120 min
respectively. The samples were analyzed using a double
beam UV-spectrophotometer and the absorbance was
recorded at 258 nm. The in-vitro dissolution studies
were performed in triplicate.
In Vivo studies
Pharmacokinetic studies
ODT tablet was subjected to bioequivalence studies
using albino rabbits and observed plasma concentration
was plotted against the time and compared with mar-
keted formulation GANATON.
The experiments were conducted as per CPCSEA
(Committee for Prevention, Control and Supervision of
Experimental Animals) guidelines. Rabbits (2.0-2.5 kg) of
either sex were kept in normal housing conditions and
were fed with commercially available diet, sprouted grams
and cabbage. The rabbits were used in the study in
accordance with a protocol approved by the Institutional
ethical committee at DIPSAR protocol number: DIPSAR/
IAEC/21/2010.
The rabbits were randomly divided into two groups of
three rabbits each. All the rabbits were fasted for 12 h
with ad libitum access to water. One group received
Marketed product GANATON whereas the other group
received the test formulation ODT F2. The test tablets
were administered in the mouth of rabbit through intra-
gastric tube and immediately 5 ml of water was ad-
ministered to facilitate swallowing of the powder and to
prevent it from sticking to the rabbit’s throat while the
marketed tablet was crushed prior to administration.
Table 3 Physical properties of Microspheres of Itopride HCl* (Mean±SD, n =3)













B2 29.35 ± 1.67 0.58 ± 0.02 0.71 ± 0.12 16.32 ± 0.55 1.56 ± 0.02 Fair
C3 27.21 ± 1.34 0.56 ± 0.15 0.67 ± 0.03 18.49 ± 0.19 1.36 ± 0.01 Good
D3 30.56 ± 1.56 0.61 ± 0.05 0.68 ± 0.04 19.57 ± 0.22 1.28 ± 0.04 Fair
E3 24.87 ± 0.89 0.52 ±0.12 0.65 ± 0.02 14.09 ± 0.44 1.15 ± 0.02 Excellent
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vein into eppendorf tubes containing EDTA at time
intervals of 5, 15, 30, 45, 60, 120 min and 4, 6, 8, 12, 16
and 24 h post administration. The blood was immedi-
ately centrifuged at 3500 rpm for 30 min at 0°C and
plasma was stored at −20°C until HPTLC analysis. To
0.5 ml aliquot of plasma, 0.5 ml of ethyl acetate was
added, centrifuged at 3500 rpm for 40 min at 0°C. The
supernatant was separated. From this supernatant ethyl
acetate was allowed to evaporate. When the samples
were dried completely they were reconstituted with mo-
bile phase (chloroform: methanol, 9:1) and kept frozen
until analyzed. The plasma drug content was analyzed
by HPTLC (CAMAG, Switzerland). Reconstituted sam-
ple of 1, 2, 3, 4, 5, 6, 7 and 8 μL was spotted in the bands
of 4 mm width using a CAMAG microlitre syringe - vol-
ume of 100 μL, on to the precoated silica gel aluminium
plate using Linomat V sample applicator. The plate was
allowed to develop in linear ascending mode in CAMAG
twin trough glass chamber saturated with the mobile
phase. The saturation time for mobile phase was chosenFigure 1 Dissolution profiles of Itopride HCl taste-masked
microspheres in pH 1.2 hydrochloric acid buffer and pH 6.8
phosphate buffer. Each value represents an average of three
determinations. (Mean± SD,n = 3).at 30mins. The chromatogram run was 8 cm. The devel-
oped TLC plate was scanned on a CAMAG TLC Scan-
ner III in the absorbance mode of 258 nm by using a
deuterium lamp as a source of radiation. Pharmacoki-
netic parameters for Itopride following administration
were determined from plasma concentration-time data.
The pharmacokinetic profile of the formulation was
compared with the marketed formulation administered
orally to the other group of animals.
The pharmacokinetic parameters, namely, maximum
plasma concentration (Cmax) and time to reach Cmax (Tmax)
were obtained directly from the plasma concentration–
time data. The area under the plasma concentration–
time curve from 0 to 24 h (AUC0—24 h) was calculated
by the trapezoidal rule.
Stability studies
The tablets of the formulation (F2) were subjected to sta-
bility studies. During the study period of 40°C/75% RH for
a specific time period up to 30 days, several parameters like
hardness, friability, in vitro dispersion and drug content
uniformity were evaluated at 1, 2, 3 and 4 weeks time
interval for possible instability problems [28].
Results and discussion
The taste masking of Itopride HCl was carried out by
coating the drug with Eudragit EPO polymer using solv-
ent evaporation method that is not only a one step pro-
cess but can be easily controlled and scaled up. Eudragit
EPO was used as a taste masking agent because it dis-
solves at a pH of less than 5 such as in the stomach (pH
1–3) to release the drug [29]. As the polymer does not
dissolve in the buccal cavity (pH 5.8-7.4), the coated drug
remains intact to produce good taste masking. Mag-
nesium stearate was used to prevent electrification and
flocculation in the preparation of microspheres [9,12].
Microspheres were prepared in drug: polymer ratios
1:1, 1:2, 1:3, 1:4, 1:5 as shown in Table 1. The amount of
the drug released from the microspheres in simulated
salivary fluid in 60 sec was considered. When the drug/
polymer ratio was increased from 1:2 to 1:3 or 1:4 or
1:5, microspheres showed almost the same drug release
profile in simulated salivary fluid (1.61%, 1.57%, 1.51%
Figure 2 Scanning Electron Micrographs of a) Itopride HCl Crystals, b) Itopride HCl-loaded Microspheres (batch E3).
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from 1:2 to 1:1, a sharp increase of drug release was
observed (6.31%). Therefore, the ratio 1:2 was considered
to be the most suitable with respect to taste masking, and
microspheres consisting of Itopride hydrochloride and
EudragitW EPO (1: 2) were further evaluated for other
parameters.The prime parameters for selection of batches were
based on particle size, loading efficiency and drug con-
tent and these were evaluated (Table 2). From the aver-
age diameter (Dav) of microspheres determined by sieve
analysis, it was found that on increasing the stirring rate,
amount of acetone and liquid parafin, the mean diam-
eter of the microspheres was found to decrease. A
Figure 3 FTIR of Itopride HCl, Drug+ Eudragit EPO, Drug-loaded microspheres E3 (drug-polymer ratio 1:2), Drug+Magnesium stearate,
Eudragit EPO.
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in failure of batch as seen in batch E1. All microspheres
varied in the size from batch to batch. Microspheres
were spherical in the size range of 300–425 μm (fraction
# 40/50) and 212–300 μm (# 50/70, major fraction) and
microspheres of other sieve fractions 125–150 μmFigure 4 DSC of Eudragit EPO, Drug-loaded microspheres (drug-polym(# 100/120) and 125–106 μm (# 120/140) were not
perfect spheres.
Further, batches of microspheres were evaluated for
bulk density, tapped density, angle of repose, Carr’s con-
solidation index and Hausner ratio. The results of pow-
der flow properties (Table 3) clearly indicated good flower ratio 1:2), Itopride HCl.
Table 4 Composition of Itopride HCl Orodispersible tablet formulations
Tablet ingredients (mg)/Formulation code F-1 F-2 F-3
Microspheres containing Itopride HCl equivalent to 50 mg 196.6 196.6 196.6
Crospovidone (XL10) 20 28 40
Mannitol (Pearlitol) 173.4 165.4 153.4
Sodium stearyl fumarate 4 4 4
Aspartame 2 2 2
Talc 4 4 4
Total weight 400 400 400
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drug content and loading efficiency, average size, flow
properties and estimation of bitter taste of microspheres,
batch E3 was considered to be optimum and was there-
fore selected for further characterization and tabletting.
Dissolution studies of Itopride HCl microspheres
(Batch E3) were performed in two different pH media
(pH 1.2 hydrochloric acid buffer and pH 6.8 phosphate
buffer (Figure 1). Eudragit EPO is soluble in an acidic
environment by formation of salts. Therefore, drug re-
leased from the microspheres very rapidly in pH 1.2
medium such that approximately 90% of the drug was
released within 10 min. Drug release in pH 6.8 buffer
was comparatively slower than that in pH 1.2 medium.
About 2.6% drug released in 10 min in pH 6.8 medium.
Eudragit EPO is insoluble at pH greater than 5 but it
becomes permeable and allows the release of Itopride
HCl. The gastric emptying time ranges from 32–87 min
in fasted states for particles with a size in the micron
range and the corresponding value is 34–75 min in fed
state [30]. Therefore, it is expected that as soon as the
polymer dissolves in the acidic contents of stomach,
drug will be released in stomach followed by absorption
from the gastrointestinal tract.
Scanning Electron Microscopy (SEM) analysis of Ito-
pride HCl showed existence of characteristic prism like
and needle like crystals as well as broad particle size
distribution (Figure 2a). The structural and surfaceTable 5 Evaluation of Itopride HCl Orodispersible tablets* (M
Evaluation parameters/Formulation code F-1
Weight Variation (mg) 399.8 ± 0
Hardness (Kg/cm2) 4.9 ± 0
Thickness (mm) 4.22 ± 0
Friability (%) 0.74 ± 0
Drug content (%) 95.52 ± 0
Water Absorption ratio (%) 78.87 ± 1
Wetting time (sec) 32 ±2
In vitro Dispersion time (sec) 18 ± 1
In vitro Disintegration time (sec) 36
Moisture uptake (%) 0.71 ± 0morphology of batch (E3) of microspheres having drug
and polymer ratio of 1:2 showed the regularly spherical
nature of microspheres with a narrow size distribution
(Figure 2b) thereby confirming the encapsulation of
Itopride HCl.
FTIR spectra of Itopride HCl, Eudragit EPO, physical
admixture of Itopride HCl plus Eudragit EPO and drug
loaded microspheres were recorded (Figure 3). FTIR
spectrum of Itopride HCL showed characteristic peaks
such as 1267.97 cm-1 for C-O-C asymmetrical ether
stretching (alkyl stretching), 1028.84 cm-1 for C-O-C
asymmetrical ether stretching (aryl ethers), 3281.29 cm-1
and 3226.33 cm-1 for NH stretching, 1631.48 cm-1 for NH
bending, 1651.73 cm-1 for C=O stretching, 1147.44 cm-1
for C-N stretching and 2942.84 cm-1 and 2965.02 cm-1
for C-H. FTIR spectrum of microspheres showed some
of the characteristic peaks of Itopride HCL such as
1270 cm-1 for C-O-C asymmetrical ether stretching
(alkyl stretching), 1020 cm-1 for C-O-C asymmetrical
ether stretching (aryl ethers), 1149 cm-1 for C-N stretch-
ing, thus confirming that no interaction of drug occurred
with the components of the formulation. The FTIR spec-
trum of the physical admixture of drug plus polymer
showed no significant shift or reduction in intensity of
peaks of Itopride HCl at 1268.93 cm-1, 3281.29 cm-1,
1631.48 cm-1, 1651.73 cm-1, 1148 cm-1 and 2959.23 cm-1.
FTIR spectroscopic studies indicated that the drug is
compatible with the polymer.ean± SD, n = 6)
F-2 F-3
.83 400± 2.34 401.2 ± 2.38
.5 4.5 ± 0.7 5.7 ± 0.4
.03 4.24 ± 0.04 4.18 ± 0.02
.04 0.55 ± 0.05 0.63 ± 0.01
.07 98.38 ±0.09 96.86 ± 0.02
.14 84.72 ±1.10 74.47 ±1.81
16 ± 1 20± 2
9± 1 14± 0.5
18 24
.13 0.75 ± 0.25 0.82 ± 0.19
Figure 5 FT-IR of Itopride HCl, Crospovidone, crushed ODT (F2), Drug+Crospovidone.
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and polymer, thermal analysis was carried out by using
DSC. The melting point of drug was confirmed from the
endothermic peak of Itopride at 197°C in DSC analysis.
DSC thermograms of Itopride HCl, Eudragit EPO and
drug-loaded microspheres (E3) showed that there were
no changes in the endotherms (Figure 4). The drug
exhibited a small melting endotherm in the drug-loaded
microspheres (E3) formulation. These slight changes in
the melting endotherm of the drug may be attributed to
the mixing process, which lowers the purity of each
component in the mixture, thus resulting in slightlyFigure 6 DSC of Itopride HCl, crushed ODT (F2), Drug+Crospovidonebroader and lower melting points, but not truly repre-
senting any incompatibility [31].
During formulation of orodispersible tablets of taste
masked microspheres, three formulations with varying
concentration of superdisintegrant: crospovidone (5, 7
and 10%w/w) were chosen on the basis of disintegration
time of tablets (Table 4). Increasing the amount of Cros-
povidone from 5 (F1) to 7%w/w (F2) resulted in a de-
crease in the disintegration time of the tablets from
36 sec to 18 sec. However, further increase in the con-
centration to 10%w/w (F3) led to increase in disinteg-
ration time to 24 sec probably due to higher water, Crospovidone.
Table 6 Dissolution profile of Orodispersible tablets (F2)
and conventional tablet (Ganaton)*(Mean± SD, n = 3)






2 73.6 ± 0.4 21.7 ± 0.9
5 84.6 ± 0.6 39.4 ± 0.2
10 98.5 ± 0.5 62.2 ± 0.9
15 100.5 ± 0.6 69.0 ± 0.2
30 100.7 ± 0.2 80.0 ± 0.4
45 100.7 ± 0.8 88.6 ± 0.9
60 101.3 ± 0.7 91.6 ± 0.4
90 101.4 ± 0.8 97.9 ± 0.3
120 101.1 ± 0.2 98.9 ± 0.8
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http://www.darujps.com/content/20/1/24requirement by a larger amount of Crospovidone, which
consequently transformed into swelling force for rapid
disintegration of the tablet. The obtained results were
similar to the findings of Khan et al., 2007 [3] and Patel
et al., 2004 [32]. Therefore, the suitable concentration of
crospovidone was found to be 7%w/w for formulation of
orodispersble tablet that showed minimal disintegration
time of 18 seconds. Water insoluble diluents such as
microcrystalline cellulose and dicalcium phosphate were
not used in the study as they are expected to cause an
unacceptable feeling of grittiness in the mouth. Among
the soluble diluents, mannitol which is a hexahydric al-
cohol related to mannose was also used in the tablet for-
mula as taste masking agent. Mannitol was also selected
considering its advantages in terms of easy availability
and negative heat of dissolution.Figure 7 In-Vitro release profile of conventional marketed
tablet (Ganaton) and formulation (F2) prepared using
Crospovidone 7% and Itopride; Eudragit ratio of 1:2 in pH 1.2
HCl medium; errors bar indicate S.D, n = 3.The tablets prepared by direct compression method
were found to be free from capping, chipping and stick-
ing. The prepared tablets were evaluated for various
physical parametric tests (Table 5). The thickness of all
the tablets was found in range of 4.18 to 4.24 mm and
was within the prescribed limits of IP 1996 (±5%) [30].
Hardness of the all tablets was between 4.5–5.7 Kg/cm2
during compression and was considered optimum for
ODTs [32]. The average weights of tablets were found to
be 399–401 mg. The acceptable weight range is ± 5% as
per IP [22] for uniformity of weight thus indicating
consistency in the preparation of the tablets and min-
imal batch to batch variation. The friability of all the for-
mulations was found to be between 0.55 to 0.74%, which
was found to be with in the pharmacopoeial requirement
[33] (i.e. not more than 1%) indicating good mechan-
ical resistance of tablet sufficient to withstand the rig-
ors of transportation and handling. The drug content
estimation data for all the batches were also found to
be within the pharmacopoeial limit (i.e. 95.52 to
98.38%).
Wetting time is used as an indicator of the ease of the
tablet disintegration in buccal cavity. It was observed
that wetting time of tablets was in the range of 16 to 32
seconds which is desirable for ODT. Water absorption
ratio, which is an important criteria for understanding
the capacity of disintegrants to swell in presence of little
amount of water, was calculated. It was found to be in
the range of 74–84% which was considered to be
optimum for an oro-dispersible tablet. Moisture uptake
by tablets was found to be in the range of 0.71–0.82%
and was considered satisfactory for an oro-dispersible
tablet. All the formulations complied with the in vitro
dispersion and disintegration time requirement of 60 sec
for orodispersible tablets as per European Pharmacopoeia
[34]. The formulation F2 containing crospovidone (7%w/w)
had the least dispersion and disintegration time of 9 and
18 sec respectively.
Thus, formulation F2 possessed good disintegrating
property among all formulations which was evaluated for
in vitro disintegration, wetting time, in vitro dispersion
time and in vivo studies.
Itopride HCl, crospovidone, crushed ODT (F2) and
physical ad-mixture of drug plus Crospovidone was
characterized by FTIR spectral analysis for any physical
as well as chemical alteration of the drug characteris-
tics (Figure 5). From the results, it was concluded that
there was no interference in the functional groups as
following principle peaks of the Itopride HCl such as at
3288.04 cm–1, 2969.84 cm–1, 2938.02 cm–1, 1631.48 cm–1,
1262.18 cm–1 and 1041.37 cm–1 were found in the spectra
of the crushed ODT. All the peaks of Itopride HCl were
found to be unaltered in the spectra of the drug-
crospovidone physical admixture.
Figure 8 In vivo plasma profile comparison of GANATON and F2 prepared using crospovidone 7% and Itopride; Eudragit ratio of 1:2 in
albino rabbits; errors bar indicate S.D, n = 3.
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http://www.darujps.com/content/20/1/24In DSC thermal analysis, Itopride HCl exhibited melt-
ing peak at 197.07°C, while in formulation F2 the drug
exhibited a small melting peak at 195.80°C. These slight
changes in the melting endotherm of the drug may be
attributed to the mixing process, which lowers the purity
of each component in the mixture, thus resulting in
slightly broader and lower melting points, but not truly
representing any incompatibility [31]. However, appear-
ance of no new peak and only a slight shift in peak of
drug + crospovidone, suggested absence of interaction
between drug and other excipients (Figure 6).
From the cumulative percentage drug release of ODT
formulation F2 and conventional tablet formulation
(GANATON) available in the market, it was observed
that in the first 2 min, only 21.7% drug was released
from GANATON tablet while it was 73.6% in case of
ODT F2 (Table 6). At the end of 10 min, 98.5% drug
was released from F2 as compared to conventional tablet
formulation in which only 62.2% drug was released
(Figure 7). Thus, the release rate of Itopride hydrochlor-
ide was enhanced by formulating ODTs by using crospo-
vidone (7%w/w) as superdisintegrant. According to the
FDA guidance, value of similiarity factor (f2) between 50
and 100 ensure sameness or equivalence of the two dis-
solution profiles. The vaue of similiarity factor was foundTable 7 Pharmacokinetic parameters of Orodispersible
tablet (F2) and conventional tablet (Ganaton) in albino
rabbits* (Mean± SD, n = 3)
Parameter Formulation F2 Ganaton tablet
Cmax (ng/ml) 270 ± 4.5 248 ± 5.6
Tmax (min) 30 45
AUC0-t (ng.h/ml) 123.98 ± 6.3 107.78 ± 5.3to be 52 which indicate comparative equivalence with
reference formulation.
Further, the formulation F2 and GANATON were sub-
jected to in vivo pharmacokinetic studies to assess the
bioequivalence. The mean plasma concentration as
assessed by HPTLC as a function of time after oral ad-
ministration of single animal dose of Itopride HCl imme-
diate release tablets (GANATON) and oral disintegrating
tablet (F2) is shown in Figure 8. The pharmacokinetic
parameters as assessed by HPTLC for both formulations
are illustrated in Table 7. The absorption from oral disin-
tegrating tablet (F2) was faster compared to GANATON
both showing Tmax of 30 and 45 min respectively. The
corresponding drug plasma concentration in rabbits after
administration of F2 and Marketed tablet was 270 ng/ml
and 248 ng/ml respectively.
The preliminary results of stability studies carried out
on formulation (F2) at 40°C/75% RH for a specific time
period upto 30 days are given in Table 8. The dispersion
time after 1, 2, 3 and 4 weeks of storage were found to
be within USFDA limits [35]. Also, no significant loss in
the drug content was found at the end of one month.
Hardness and friability values were also found to be
within the pharmacopoeial range after 1 month storage
at 40°C.
Conclusions
This study demonstrated that the prepared Itopride HCl
oral disintegrating tablets possess short in vitro disinte-
gration time and improved dissolution patterns as well
as pharmacokinetic behavior in rabbits compared to the
conventional product available in market. Therefore, it
can be concluded that taste masking and rapid disinte-
gration of tablets formulated in this investigation may
Table 8 Stability studies of Orodispersible tablets ((Mean± SD, n = 6)
Time Evaluation parameters (F2)
Hardness (kg/cm2) Drug content % Friability (%) In-vitro Dispersion time (sec)
After 1 week 4.2 ±0.7 97.65 ± 0.04 0.50 ± 0.09 9 ± 1
After 2 week 4.1 ±0.9 95.99 ±0.04 0.47 ± 0.05 8 ± 0.5
After 3 week 4.0 ±0.6 95.47 ± 0.08 0.45 ± 0.01 8 ± 1
After 4 week 3.9 ±0.5 94.80 ± 0.02 0.42 ± 0.03 7 ± 0.9
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http://www.darujps.com/content/20/1/24possibly help in administration of Itopride HCl in a more
palatable form without water during emesis. Thus, the
present drug delivery technology could be expected to
have higher patient compliance over conventional tablets
thereby necessitating the extension of this technology to
development of other potential drug candidates.
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